Healthcare
ByCan Bristol Myers Squibb’s $330 Million AI Investment in 2025 — Powered by Strategic Partnerships — Accelerate Discovery, R&D and Commercial Impact in 2026?
Global – December 31, 2025 — Bristol Myers Squibb (BMS) significantly expanded its commitment to artificial intelligence (AI)…
Can GSK’s $340 Million AI Investment in 2025 — Backed by Strategic Collaborations — Accelerate Discovery, R&D and Commercial Growth in 2026?
Global – December 31, 2025 — GlaxoSmithKline plc (GSK) significantly expanded its use of artificial intelligence (AI) throughout…
Can AstraZeneca’s $390 Million AI Investment in 2025 — Fueled by Strategic Partnerships — Accelerate Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — AstraZeneca plc significantly expanded its commitment to artificial intelligence (AI) throughout 2025,…
Can Merck’s $300 Million AI Investment in 2025 — Fueled by Strategic Partnerships — Accelerate Innovation, R&D and Commercial Success in 2026?
Global – December 31, 2025 — Merck & Co., Inc. significantly expanded its commitment to artificial intelligence (AI)…
Is AstraZeneca’s Acquisition of Modella AI at JPM 2026 a Signal That Pharma Is Internalizing AI for R&D?
Cambridge, U.K. | January 2026 AstraZeneca has taken a decisive step to deepen its artificial intelligence capabilities, announcing…
Is AbbVie’s $5.6 Billion RemeGen Licensing Deal at JPM2026 a Bet on the Next Wave of Immuno-Oncology?
Chicago, U.S. | January 2026 AbbVie has reinforced its commitment to externally sourced innovation with a major oncology…
